Tourmaline Bio Inc

Tourmaline Bio Inc(TRML)の財務

$47.980

0.000 (0.00%)終値時点

TRML の収益性とマージン

Evaluating the bottom line, Tourmaline Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -29.62%, provide a clear picture of how effectively TRML converts its operational activities into shareholder value.

TRML の同業比較

In the context of the broader market, TRML competes directly with industry leaders such as IMTX and ELVN. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, TRML's gross margin of N/A stands against IMTX's 100.00% and ELVN's N/A. Such benchmarking helps identify whether Tourmaline Bio Inc is trading at a premium or discount relative to its financial performance.

Financials

FY2025Q2
YoY:
+18.22%
-25.97M
Operating Profit
FY2025Q2
YoY:
+32.05%
-23.09M
Net Income after Tax
FY2025Q2
YoY:
+32.35%
-0.90
EPS - Diluted
FY2025Q2
YoY:
+12.57%
-20.27M
Free Cash Flow

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める